SIRT3 Expression as a Biomarker for Better Prognosis in Gastric Cancer

详细信息    查看全文

• 作者：Kuo-Hung Huang (1) (2)
  Chia-Chi Hsu (3)
  Wen-Liang Fang (1) (2)
  Chin-Wen Chi (3) (4)
  Ming-Ta Sung (4)
  Hwa-Li Kao (1)
  Anna Fen-Yau Li (6)
  Pen-Hui Yin (4)
  Muh-Hwa Yang (2) (5)
  Hsin-Chen Lee (3)
  
• 刊名：World Journal of Surgery
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：38
• 期：4
• 页码：910-917
• 全文大小：2,919 KB
• 参考文献：1. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 127:2893-917 CrossRef
  2. Wu CW, Hsiung CA, Lo SS et al (2006) Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol 7:309-15 CrossRef
  3. Hirschey MD, Shimazu T, Goetzman E et al (2010) SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464:121-25 CrossRef
  4. Lavu S, Boss O, Elliott PJ et al (2008) Sirtuins—novel therapeutic targets to treat age-associated disease. Nat Rev Drug Discov 7:841-53 CrossRef
  5. Someya S, Yu W, Hallows WC et al (2010) Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143:802-12 CrossRef
  6. Alhazzazi TY, Kamarajan P, Joo N et al (2011) Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 117:1670-678 CrossRef
  7. Ashraf N, Zino S, Macintyre A et al (2006) Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 95:1056-061 CrossRef
  8. Kim HS, Patel K, Muldoon-Jacobs K et al (2010) SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17:41-2 CrossRef
  9. Finley LW, Carracedo A, Lee J et al (2011) SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 19:416-28 CrossRef
  10. Zhang YY, Zhou LM (2012) SIRT3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem Biophys Res Commun 423:26-1 CrossRef
  11. Zhang CZ, Liu L, Cai M et al (2012) Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One 7:e51703 CrossRef
  12. Ming SC (1977) Gastric carcinoma: a pathological classification. Cancer 39:2475-485 CrossRef
  13. American Joint Committee on Cancer (2010) AJCC cancer staging manual, 7th edn. Springer, New York CrossRef
  14. Alhazzazi TY, Kamarajan P, Verdin E et al (2011) SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta 1816:80-8
  15. Bell EL, Emerling BM, Ricoult SJ et al (2011) Sirt3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene 30:2986-996 CrossRef
  16. Gibellini L, Pinti M, Nasi M et al (2010) Interfering with ROS metabolism in cancer cell: the potential role of quercetin. Cancer 2:1288-311 CrossRef
  
• 作者单位：Kuo-Hung Huang (1) (2)
  Chia-Chi Hsu (3)
  Wen-Liang Fang (1) (2)
  Chin-Wen Chi (3) (4)
  Ming-Ta Sung (4)
  Hwa-Li Kao (1)
  Anna Fen-Yau Li (6)
  Pen-Hui Yin (4)
  Muh-Hwa Yang (2) (5)
  Hsin-Chen Lee (3)
  
  1. Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
  2. Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, 112, Taiwan
  3. Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, 112, Taiwan
  4. Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan
  6. Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan
  5. Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, 112, Taiwan
  
• ISSN：1432-2323

文摘

Background SIRT3—mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase sirtuin-3—plays an important role in regulating cell metabolism and carcinogenesis. The role of SIRT3 in gastric cancer has not yet been investigated. Methods A total of 221 gastric cancer patients who underwent curative surgery were enrolled at the Department of Surgery, Taipei Veterans General Hospital. SIRT3 expression in gastric tissues and tumors were examined in these patients using immunohistochemical staining. Clinicopathologic characteristics and survival were analyzed and compared in gastric cancer patients with or without SIRT3 expression. Results The 5-year survival rates of patients with or without SIRT3 expression were 51.2 and 39.1?%, respectively (p?=?0.005). The 5-year disease-free survival rates of patients with or without SIRT3 expression were 49.6 and 38.0?%, respectively (p?=?0.010). Microscopic features showed that there are more poor cell differentiation (p?=?0.001), more diffuse-type Lauren’s histology (p?=?0.018), and more scirrhous-type stromal reactions (p?=?0.027) in gastric cancer without SIRT expression. Multivariate analysis with overall survival as an endpoint showed that age (p?<?0.001), Lauren’s histology (p?=?0.007), stromal reaction (p?=?0.035), TNM pathologic N category (p?<?0.001), and SIRT3 expression (p?<?0.001) were significantly correlated with gastric cancer. Conclusions Gastric cancer patients with SIRT3 expression have a better prognosis than those without. SIRT3 expression is an independent prognostic marker for overall survival and may act as a tumor suppressor in gastric cancer.